12 Month Price Forecast For OM
Distance to OM Price Forecasts
OM Price Momentum
🤔 Considering Outset Medical (OM)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 11:39 AM UTC
OM Analyst Ratings & Price Targets
Based on our analysis of 11 Wall Street analysts, OM has a consensus that is bullish. The median price target is $3.50, with forecasts ranging from $3.00 to $6.00. Currently, there are 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
With OM currently trading at $0.78, the median price forecast suggests a 348.7% upside. The most optimistic forecast comes from Shagun Singh at RBC Capital, projecting a 669.2% upside, while Shagun Singh at RBC Capital provides the most conservative target, suggesting a 284.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OM Analyst Consensus
OM Price Target Range
Latest OM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 7, 2025 | RBC Capital | Shagun Singh | Sector Perform | Reiterates | $3.00 |
| Aug 8, 2024 | RBC Capital | Shagun Singh | Sector Perform | Downgrade | $3.00 |
| Aug 8, 2024 | TD Cowen | Joshua Jennings | Buy | Maintains | $3.00 |
| Jun 21, 2024 | RBC Capital | Shagun Singh | Outperform | Upgrade | $6.00 |
| Apr 8, 2024 | BTIG | Maria Thibault | Buy | Initiates | $6.00 |
| Jan 12, 2024 | RBC Capital | Shagun Singh | Sector Perform | Downgrade | $6.00 |
| Dec 4, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $5.50 |
| Nov 14, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $5.00 |
| Oct 13, 2023 | RBC Capital | Shagun Singh | Outperform | Maintains | $17.00 |
| Oct 13, 2023 | B of A Securities | Travis Steed | Underperform | Downgrade | $3.00 |
| Oct 13, 2023 | Stifel | Rick Wise | Buy | Maintains | $6.00 |
| Aug 24, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $19.00 |
| Aug 17, 2023 | CL King | Kristen Stewart | Neutral | Initiates | $0.00 |
| Aug 17, 2023 | RBC Capital | Shagun Singh | Outperform | Reiterates | $29.00 |
| Aug 3, 2023 | Morgan Stanley | Equal-Weight | Maintains | $0.00 | |
| May 31, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $23.00 |
| May 15, 2023 | RBC Capital | Shagun Singh | Outperform | Reiterates | $29.00 |
| May 4, 2023 | RBC Capital | Shagun Singh | Outperform | Maintains | $29.00 |
| Jan 6, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $27.00 |
| Nov 11, 2022 | RBC Capital | Shagun Singh | Outperform | Initiates | $23.00 |
Stocks Similar to Outset Medical Inc
The following stocks are similar to Outset Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Outset Medical Inc (OM) Financial Data
Outset Medical Inc has a market capitalization of $42.72M with a P/E ratio of -0.2x. The company generates $114.73M in trailing twelve-month revenue with a -122.8% profit margin.
Revenue growth is -5.6% quarter-over-quarter, while maintaining an operating margin of -83.2% and return on equity of -141.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Outset Medical Inc (OM) Company Overview
About Outset Medical Inc
Develops innovative hemodialysis systems.
The company generates revenue by developing and selling its Tablo Hemodialysis System, which is designed for both acute and home dialysis settings. It also earns income through the sale of related consumables and its Tablo Data Ecosystem, which includes various customer and patient-facing platforms that enhance the dialysis experience.
Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. The company focuses on providing integrated solutions for dialysis care, improving accessibility and efficiency for patients and healthcare providers.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
480
CEO
Ms. Leslie L. Trigg
Country
United States
IPO Year
2020
Website
www.outsetmedical.comOutset Medical Inc (OM) Latest News & Analysis
A company has secured new debt financing of up to $125 million, maturing in 2030, and plans to use it to retire $200 million in prior debt.
New debt financing improves liquidity and reduces interest expenses by retiring older debt, potentially enhancing profitability and creditworthiness, impacting stock performance positively.
Bragar Eagel & Squire is investigating claims against Outset Medical (NASDAQ: OM) for potential breaches of fiduciary duties related to a class action filed for the period from August 1, 2022, to August 7, 2024.
The investigation into Outset Medical's board could signal potential legal and financial risks, impacting stock performance and shareholder confidence.
Outset Medical, Inc. (Nasdaq: OM) will present at the 2024 Stifel Healthcare conference on November 19, 2024, at 10:20 a.m. ET, discussing its innovative dialysis technology.
Outset Medical's presentation at a major healthcare conference highlights its innovative dialysis technology, potentially attracting investor interest and impacting stock performance.
Outset Medical Inc. (NASDAQ:OM) will hold its Q3 2024 results conference call on November 6, 2024, at 5:00 PM ET, featuring key company executives and analysts.
Outset Medical's Q3 results call indicates upcoming financial insights, affecting stock performance and investor sentiment. Analyst participation suggests market interest and potential volatility.
Outset Medical, Inc. (Nasdaq: OM) reported its Q3 2024 financial results, focusing on its innovative technology aimed at lowering dialysis costs and complexity.
Outset Medical's Q3 financial results indicate its market performance and potential impact on stock value, particularly in the growing dialysis technology sector.
Outset Medical, Inc. reported a quarterly loss of $0.39 per share, better than the expected loss of $0.42, improving from a loss of $0.71 per share a year earlier.
Outset Medical's smaller-than-expected loss indicates improving financial health, potentially boosting investor confidence and market sentiment. Year-over-year loss reduction suggests operational progress.
Frequently Asked Questions About OM Stock
What is Outset Medical Inc's (OM) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Outset Medical Inc (OM) has a median price target of $3.50. The highest price target is $6.00 and the lowest is $3.00.
Is OM stock a good investment in 2025?
According to current analyst ratings, OM has 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.78. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for OM stock?
Wall Street analysts predict OM stock could reach $3.50 in the next 12 months. This represents a 348.7% increase from the current price of $0.78. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Outset Medical Inc's business model?
The company generates revenue by developing and selling its Tablo Hemodialysis System, which is designed for both acute and home dialysis settings. It also earns income through the sale of related consumables and its Tablo Data Ecosystem, which includes various customer and patient-facing platforms that enhance the dialysis experience.
What is the highest forecasted price for OM Outset Medical Inc?
The highest price target for OM is $6.00 from Shagun Singh at RBC Capital, which represents a 669.2% increase from the current price of $0.78.
What is the lowest forecasted price for OM Outset Medical Inc?
The lowest price target for OM is $3.00 from Shagun Singh at RBC Capital, which represents a 284.6% increase from the current price of $0.78.
What is the overall OM consensus from analysts for Outset Medical Inc?
The overall analyst consensus for OM is bullish. Out of 11 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $3.50.
How accurate are OM stock price projections?
Stock price projections, including those for Outset Medical Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
